Stock 688238 OBIO TECHNOLOGY (SHANGHAI) CORP., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Obio Technology (Shanghai) Corp., Ltd.

Equities

688238

CNE1000059N9

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-05-30 EDT 		5-day change 1st Jan Change
5.65 CNY +3.48% Intraday chart for Obio Technology (Shanghai) Corp., Ltd. +3.29% -37.15%
05-30 OBiO Technology Officially Launches the Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases CI
05-16 Obio Technology's Shareholders to Offload Up to 1.5% Stake MT

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 9,400 5,820 3,658 - -
Enterprise Value (EV) 1 9,400 5,820 3,658 3,658 3,658
P/E ratio 230 x -45.2 x -31.4 x 319 x -
Yield - - - - -
Capitalization / Revenue 32.3 x 27.3 x 10.7 x 8.14 x 9.86 x
EV / Revenue 32.3 x 27.3 x 10.7 x 8.14 x 9.86 x
EV / EBITDA 143 x -48.7 x 80.6 x 41.3 x -
EV / FCF - -9.14 x -17.2 x -22.9 x 114 x
FCF Yield - -10.9% -5.82% -4.37% 0.87%
Price to Book 4.33 x 2.82 x 1.88 x 1.44 x -
Nbr of stocks (in thousands) 641,146 647,433 647,433 - -
Reference price 2 14.66 8.990 5.650 5.650 5.650
Announcement Date 23-02-23 24-02-23 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 - 291.3 213 340.9 449.2 371
EBITDA 1 - 65.77 -119.4 45.36 88.64 -
EBIT 1 - 41.71 -156.1 -123 13 -
Operating Margin - 14.32% -73.26% -36.09% 2.89% -
Earnings before Tax (EBT) 1 - 41.62 -156.2 -123 5.5 -
Net income 1 54.26 39.03 -128 -116 10.17 -
Net margin - 13.4% -60.09% -34.03% 2.26% -
EPS 2 0.1077 0.0638 -0.1990 -0.1800 0.0177 -
Free Cash Flow 1 - - -637 -213 -160 32
FCF margin - - -299.01% -62.49% -35.62% 8.63%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 22-03-02 23-02-23 24-02-23 - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 - - -637 -213 -160 32
ROE (net income / shareholders' equity) - 2.12% -6.06% -0.58% 1.36% -
ROA (Net income/ Total Assets) - 1.75% -4.98% -4.5% -0.25% -
Assets 1 - 2,233 2,573 2,578 -4,067 -
Book Value Per Share 2 - 3.390 3.190 3.000 3.930 -
Cash Flow per Share 2 - 0.0300 -0.1400 -0.1600 0.1200 -
Capex 1 - 484 547 103 67.5 38
Capex / Sales - 166.29% 256.71% 30.22% 15.03% 10.24%
Announcement Date 22-03-02 23-02-23 24-02-23 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Obio Technology (Shanghai) Corp., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
5.65 CNY
Average target price
8.2 CNY
Spread / Average Target
+45.13%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
OBIO TECHNOLOGY (SHANGHAI) CORP., LTD. Stock Obio Technology (Shanghai) Corp., Ltd.
-37.15% 505M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 162B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 688238 Stock
  4. Financials Obio Technology (Shanghai) Corp., Ltd.